本帖最后由 老马 于 2012-1-13 21:20 编辑 . v) w- ~! J% y! m) K( @
7 B- m! J; Q. N- ~$ ?爱必妥和阿瓦斯丁的比较
3 m6 i; X3 i, a" n! y- l9 k _
0 i; \+ I# X# m o7 y0 Fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" x8 i o: _5 S% n# A! ^5 o( \
& t& b6 M( a* k |. p. [! J
5 \$ O% z2 y2 h) M2 Uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 p0 d! D* x+ \# h
==================================================9 j( h7 V% y! @3 X! ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! O. R: p; I5 L5 U$ k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. Q/ p! k4 k1 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ f: C/ ^9 p5 c! U
|